2nd Neuroscience Innovation Partnering and Licensing Summit

Memo

From transformative genetic therapies in rare diseases to neuroimmunology candidates addressing residual unmet needs in MS, and novel target validation driving confidence in disease modification for neurodegeneration, best- and first-in-class neuroscience opportunities continue to shape and drive pharma investment. Returning for its second year, following the inaugural launch that attracted over 100 attendees, the 2nd Neuroscience Innovation Partnering and Licensing Summit is strategically timed to facilitate multiple high-impact, in-person meetings without the distractions of a broader, less focused setting. Who Attends This Differentiated Business Development Initiative? - Global Pharma: Heads of Business Development, Search and Evaluation, and Asset Scouting for Neuroscience - comparing pipelines and enabling technologies to fuel future innovation.- Innovative Biotech: C-level executives and BD leaders across neurodegeneration, psychiatry, neuro-oncology, and pain - seeking feedback, validation, and strategic partnerships with pharma and investors.- Investors and Venture Capital: Leaders focused on neuroscience investments with higher risk appetite - looking for insights into pharma strategy and access to breakthrough opportunities. Less competitive and more accessible, pharma can assess related programs back-to-back, while biotech has a protected opportunity to meet multiple big pharma players against the backdrop of market intelligence. URLs:Tickets: https://go.evvnt.com/3491403-2?pid=5569Brochure: https://go.evvnt.com/3491403-3?pid=5569 Prices:Drug Developer Pricing - 2 Day Pass (Conference + 15 Min Presentation): USD 6498.00,Drug Developer - 1 Day Pass (Conference): USD 3099.00,Academic Pricing - 2 Day Pass (Conference + 15 Min Presentation): USD 5524.00,Academic Pricing - 1 Day Pass (Conference): USD 2699.00 Speakers: Murali Gopalakrishnan, Global Head, Neuroscience Search and Evaluation, Corporate Strategy, AbbVie, Karen Harris, Chief Financial Officer and Head of Mission Related Investing, Alzheimer's Drug Discovery Foundation, Nicole Bjorklund, Director - Research and Grants, Association for Frontotemporal Degeneration, Annika Malmberg, Api Development Head, Biogen, Catherine Abbadie, External Innovation, Biogen, Mike Dial, Managing Director, Chugai Ventures, Stephen Zicha, Senior Director, Neuroscience, Eli Lilly, Lauren Mifflin, Principal, Company Creation, Frazier Life Sciences, David Donabedian, Executive Partner, Longwood Funds, Chris Adams, Head of Search and Evaluation Neuroscience, Novartis, Laura Ripin, Head of BD and L Transactions Neuroscience, Novartis, XiaoQian Liu, Associate Director, Business Development Search and Evaluation, Otsuka, Michaela Tolman, Commercial Development Lead, Pfizer, Vidya Nadar, Director, Sanofi, Jonathan Behr, Partner, SV Dementia Discovery Fund, Eleni Stavridi, Head Search and Evaluation, Neuroscience, Takeda, Ross Gruber, Neuroscience Search and Evaluation Lead, Takeda, Julianna Sullivan, Director of Research Alliances, The Michael J. Fox Foundation for Parkinson's Research, Danielle Feldman, Co-founder and Senior Director Corporate Development, Aliada Therapeutics, Martin Jacko, CEO, Aperture Therapeutics, Patrick Gallagher, Chief Business Officer and Head of the US, Argo Biopharma, Andrew Morris, Vice President, Business Development, CAMP4 Therapeutics, Arun Swaminathan, Chief Executive Officer, Coya Therapeutics, Mathias Schmidt, Executive Advisor JCR Pharmaceuticals, John Mayfield, CEO, JEO Biotech Advisors, Michael Bowen, Co-Founder and Chief Scientific Officer, Kinoxis Therapeutics, Revital Mandi Levin, Chief Executive Officer and Founder, Nanocarry, Jackie von Salm, Co-Founder and Scientific Chief and Officer, Psilera, Gerard Caelles, Chief Business Officer, Splice Bio, Alice Zhang, Chief Executive Officer and Co-Founder, Verge Genomics Category: Conferences | Science, Health and Medicine | Pharmaceuticals Date and Time: 28th April 2026 at 8:00 am to 29th April 2026 at 3:00 pm Venue details: Revere Hotel Boston Common, 200 Stuart Street, Boston, Massachusetts, 02116, United States